Dosing & Uses
Dosage Forms & Strengths
Indicated for intravesicular treatment of BCG-Refractory bladder carcinoma in situ
800 mg intravesical once weekly for 6 weeks; retain in bladder for 2 hours before voiding
Monitor q3month for recurrence/progression of CIS
Reconstitution: withdraw contents of 4 vials, each containing 200 mg in 5 mL (allowed to warm to room temp without heating), & dilute with 55 mL NS
Instill slowly via gravity flow through a urinary catheter (following sterile insertion)
Withdraw the catheter & allow patient to retain solution for 2 hours
After 2 hours, patient should void
Use caution when preparing, handling, and disposal
Serious - Use Alternative
Significant - Monitor Closely
Urinary frequency (61%)
Urinary urgency (57%)
Bladder spasm (31%)
Bladder pain (28%)
Urinary incontinence (22%)
Abd pain (5%)
Urinary retention (4%)
Back pain (3%)
Chest pain (2%)
Hypersensitivity to valrubicin, anthracyclines or other ingredients
Perforated bladder mucosa
Small bladder capacity; unable to tolerate a 75 mL instillation
Complete response in only 20%
Delaying cystectomy can lead to development of metastatic bladder cancer, which is lethal
Not for administration to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised
Evaluate status of bladder before intravesical instillation of therapy
Use with caution in patients with severe irritable bladder symptoms
Advise females of reproductive potential of potential risk to fetus and to use effective contraception
Delay valrubicin therapy for 2 weeks after transurethral resection or fulguration
Urine may be red-tinged for 24 hr post-instillation
Was unavailable since 2002 due to manufacturing problems; reintroduced 2009
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk, do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Semisynthetic analog of doxorubicin; inhibits DNA topoisomerase II, which in turn inhibits DNA synthesis; causes extensive chromosomal damage and arrests cells at the G2 phase of the cell cycle; readilly penetrate cells but does not appear to intercalate DNA
Absorption: Negligible systemic absorption
Metabolites: N-trifluoroacetyladriamycin, N-trifluoroacetyladriamycinol
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.